Recent data from a multicenter randomized trial (New Technologies for Cervical Cancer, NTCC, in Italy) comparing HPV testing with Pap cytology and using p16 cytology to triage positive HPV results suggest that immediate follow-up can be avoided in HPV-positive p16 cytology-negative women, who may be safely managed with follow-up testing within 2–3 years (15,16). Here, CDKN2A is linked to cervical cancer.